Last $16.02 USD
Change Today +0.32 / 2.04%
Volume 585.3K
KERX On Other Exchanges
KERX is not on other exchanges.
As of 12:51 PM 11/24/14 All times are local (Market data is delayed by at least 15 minutes).

keryx biopharmaceuticals (KERX) Snapshot

Previous Close
Day High
Day Low
52 Week High
08/28/14 - $18.48
52 Week Low
05/9/14 - $11.53
Market Cap
Average Volume 10 Days
Shares Outstanding
Dividend Yield

keryx biopharmaceuticals (KERX) Related Bloomberg News

View More Bloomberg News

keryx biopharmaceuticals (KERX) Related Businessweek News

No Related Businessweek News Found

keryx biopharmaceuticals (KERX) Details

Keryx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of pharmaceutical products for the treatment of renal disease in the United States. It is developing Zerenex (ferric citrate), an oral, ferric iron-based compound that has the capacity to bind to phosphate in the gastrointestinal tract and form non-absorbable complexes. The company has completed Phase III clinical program for Zerenex for the treatment of hyperphosphatemia (elevated phosphate levels) in patients with chronic kidney disease on dialysis. Zerenex has also completed a Phase II study for the management of elevated serum phosphorus levels and iron deficiency anemia in patients with stages three to five non-dialysis dependent chronic kidney disease. The company has sublicense agreements with Japan Tobacco Inc. and Torii Pharmaceutical Co., Ltd. for the development and commercialization of Zerenex in Japan. It also has strategic alliances with Panion & BF Biotech, Inc. Keryx Biopharmaceuticals, Inc. was founded in 1997 and is headquartered in New York, New York.

92 Employees
Last Reported Date: 11/6/14
Founded in 1997

keryx biopharmaceuticals (KERX) Top Compensated Officers

Chief Executive Officer, Director and Member ...
Total Annual Compensation: $475.0K
Chief Financial Officer, Principal Accounting...
Total Annual Compensation: $405.0K
Compensation as of Fiscal Year 2013.

keryx biopharmaceuticals (KERX) Key Developments

Keryx Biopharmaceuticals Announces Trade Name Auryxia(TM) for Ferric Citrate

Keryx Biopharmaceuticals Inc. announced that the U.S. Food and Drug Administration has approved the trade name Auryxia(TM) (ferric citrate) for its FDA-approved ferric citrate. Auryxia, an iron-based phosphate binder, was approved by the FDA to control serum phosphorus levels in patients with chronic kidney disease (CKD) on dialysis in September 2014.

Keryx Biopharmaceuticals Inc. Announces Results from Ferric Citrate Phase 3 Long-Term Safety Extension Study

Keryx Biopharmaceuticals Inc. announced the results from a 48-week Open Label Extension (OLE) safety study in which Ferric Citrate demonstrated long-term safety and efficacy in dialysis-dependent chronic kidney disease (CKD) patients with elevated serum phosphorus levels, or hyperphosphatemia. The results are consistent with those seen in the pivotal Phase 3 trial. The Ferric Citrate OLE study consisted of 168 patients who completed the pivotal 52-week, randomized, active control Phase 3 study. Of those enrolled, 166 patients were dosed with Ferric Citrate and 125 patients completed the OLE study lasting an additional 48 weeks. Over the 48-week OLE study period, patients received an average of 7.9 tablets a day. Ferric Citrate was administered as 1 gram tablets each containing 210 mg of ferric iron. The study was conducted in 35 U.S. sites. Safety in the study was assessed by recording and monitoring adverse events (AE), serious adverse events (SAE) and sequential laboratory data.

Keryx Biopharmaceuticals Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 10:20 AM

Keryx Biopharmaceuticals Inc. Presents at Stifel Healthcare Conference 2014, Nov-18-2014 10:20 AM. Venue: The Palace Hotel, 455 Madison Ave, New York, NY 10022, United States. Speakers: Ron Bentsur, Chief Executive Officer, Director and Member of Research & Development Committee.


Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
KERX:US $16.02 USD +0.32

KERX Competitors

Market data is delayed at least 15 minutes.

Company Last Change
No competitor information is available for KERX.
View Industry Companies

Industry Analysis


Industry Average

Valuation KERX Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 140.6x
Price/Book 14.6x
Price/Cash Flow NM Not Meaningful
TEV/Sales 129.2x

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact KERYX BIOPHARMACEUTICALS, please visit Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at